Ovarian cancer differential diagnosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 10: Line 10:
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! colspan="2" rowspan="4" |Diseases
! colspan="2" rowspan="4" |Diseases
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| colspan="7" |'''Clinical manifestations'''
! colspan="5" rowspan="2" |Para-clinical findings
! colspan="4" rowspan="2" |Para-clinical findings
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
| rowspan="3" |Age of onset
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! colspan="2" |Imaging
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunohistopathology
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunohistopathology
|-  
|-  
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptom 1
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |pelvic pain or pressure
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptom 2
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |vaginal discharge
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptom 3
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptom 3
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 1
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Pleural effusion'''
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 3
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 3
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 1
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CT scan
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CT scan
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |MRI
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |MRI
Line 36: Line 36:
| rowspan="13" style="background: #DCDCDC; padding: 5px; text-align: center;" |Ovarian
| rowspan="13" style="background: #DCDCDC; padding: 5px; text-align: center;" |Ovarian
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Serous cystadenoma/carcinoma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Serous cystadenoma/carcinoma
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 51: Line 51:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Mucinous cystadenoma/carcinoma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Mucinous cystadenoma/carcinoma
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 66: Line 66:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Endometrioma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Endometrioma
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 81: Line 81:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Teratoma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Teratoma
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 96: Line 96:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Dysgerminoma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Dysgerminoma
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 111: Line 111:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Choriocarcinoma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Choriocarcinoma
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 126: Line 126:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Yolk sac tumor
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Yolk sac tumor
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 141: Line 141:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Fibroma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Fibroma
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 156: Line 156:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Thecoma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Thecoma
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 171: Line 171:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Granulosa cell tumor
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Granulosa cell tumor
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 186: Line 186:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sertoli-lydig cell tumor
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sertoli-lydig cell tumor
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 201: Line 201:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Brenner tumor
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Brenner tumor
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 216: Line 216:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Metastasis (krukenberg)
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Metastasis (krukenberg)
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 232: Line 232:
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |Tubal
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |Tubal
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Ectopic pregnancy
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Ectopic pregnancy
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 247: Line 247:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Hydrosalpinx
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Hydrosalpinx
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 262: Line 262:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Tuberculosis salpingitis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Tuberculosis salpingitis
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 277: Line 277:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Epithelial carcinoma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Epithelial carcinoma
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 292: Line 292:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |serous tubal intraepithelial neoplasm
| style="background: #DCDCDC; padding: 5px; text-align: center;" |serous tubal intraepithelial neoplasm
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 308: Line 308:
| rowspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Uterine
| rowspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Uterine
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Myoma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Myoma
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 323: Line 323:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoma
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 338: Line 338:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pregnancy
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pregnancy
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 356: Line 356:
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |GIT
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |GIT
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Apppendiceal abscess
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Apppendiceal abscess
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 371: Line 371:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Appendiceal  neoplasm
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Appendiceal  neoplasm
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 386: Line 386:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Diverticular abscess
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Diverticular abscess
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 401: Line 401:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |GI neoplasm
| style="background: #DCDCDC; padding: 5px; text-align: center;" |GI neoplasm
| style="background: #F5F5F5; padding: 5px;" |
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 417: Line 417:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Renal
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Renal
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pelvic kidney
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pelvic kidney
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 428: Line 429:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |tract infection (UTI), obstruction, and renal calculi.
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Others
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Others
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Retroperitoneal sarcoma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Retroperitoneal sarcoma
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 444: Line 445:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Gastrointestinal symptoms, such as early satiety, obstruction,lower extremity edema, Serous ascites
| style="background: #F5F5F5; padding: 5px;" |
|}
|}


Revision as of 17:01, 24 January 2019

Ovarian cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classifications

Pathophysiology

Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Staging

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ovarian cancer differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer differential diagnosis

CDC on Ovarian cancer differential diagnosis

Ovarian cancer differential diagnosis in the news

Blogs on Ovarian cancer differential diagnosis

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Differentiating [Disease name] from other Diseases

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Age of onset Symptoms Physical examination
Lab Findings Imaging Immunohistopathology
pelvic pain or pressure vaginal discharge Symptom 3 Pleural effusion Physical exam 2 Physical exam 3 CT scan MRI
Gynecologic
Ovarian Serous cystadenoma/carcinoma
Mucinous cystadenoma/carcinoma
Endometrioma
Teratoma
Dysgerminoma
Choriocarcinoma
Yolk sac tumor
Fibroma
Thecoma
Granulosa cell tumor
Sertoli-lydig cell tumor
Brenner tumor
Metastasis (krukenberg)
Tubal Ectopic pregnancy
Hydrosalpinx
Tuberculosis salpingitis
Epithelial carcinoma
serous tubal intraepithelial neoplasm
Uterine Myoma
Sarcoma
Pregnancy
Non-gynecologic
GIT Apppendiceal abscess
Appendiceal neoplasm
Diverticular abscess
GI neoplasm
Renal Pelvic kidney tract infection (UTI), obstruction, and renal calculi.
Others Retroperitoneal sarcoma Gastrointestinal symptoms, such as early satiety, obstruction,lower extremity edema, Serous ascites

References

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Ovarian_cancer_differential_diagnosis&oldid=1540558"